0001415889-24-019468.txt : 20240710 0001415889-24-019468.hdr.sgml : 20240710 20240710173217 ACCESSION NUMBER: 0001415889-24-019468 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240708 FILED AS OF DATE: 20240710 DATE AS OF CHANGE: 20240710 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DeVaul William CENTRAL INDEX KEY: 0001780270 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38940 FILM NUMBER: 241110654 MAIL ADDRESS: STREET 1: C/O MORPHIC HOLDING, INC. STREET 2: 35 GATEHOUSE DRIVE, A2 CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Morphic Holding, Inc. CENTRAL INDEX KEY: 0001679363 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473878772 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 GATEHOUSE DRIVE A2 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 996-0955 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE A2 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Morphic Holding, LLC DATE OF NAME CHANGE: 20160712 4 1 form4-07102024_090714.xml X0508 4 2024-07-08 0001679363 Morphic Holding, Inc. MORF 0001780270 DeVaul William C/O MORPHIC HOLDING, INC. 35 GATEHOUSE DRIVE, A2 WALTHAM MA 02451 false true false false General Counsel and Secretary 1 Common Stock 2024-07-08 4 M 0 10000 4.3151 A 33029 D Common Stock 2024-07-08 4 S 0 10000 55.7907 D 23029 D Employee Stock Option (right to buy) 4.3151 2024-07-08 4 M 0 10000 0 D 2028-12-14 Common Stock 10000 103855 D The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2023. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.79 to $55.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option is fully vested. /s/ Robert Farrell, Attorney-in-Fact for William DeVaul 2024-07-10